UNIVERSITÄT ZU KÖLN

Müller, F., Lim, J.K.M., Bebber, C.M., Seidel, E., Tishina, S., Dahlhaus, A., Stroh, J., Beck, J., Yapici, F.I., Nakayama, K., Torres Fernández, L., Brägelmann, J., Leprivier, G., and von Karstedt, S. (2023. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation. Cell Death Differ 30, 442-456. doi: 10.1038/s41418-022-01096-8.

Seidel, E., & von Karstedt, S. (2022) Extrinsic cell death pathway plasticity: a driver of clonal evolution in cancer? Cell Death and Differentiation 8, Article number: 465 (review)

Montinaro, A., Areso Zubiaur, I., Saggau, J., Kretz, A-L-, Ferreira, R.M.M., Hassan, O., Kitzig, E., Müller, I., El-Bahrawy, M.A., von Karstedt, S., Kulms, D., Liccardi, G., Lemke J. & Walczak, H. (2021) Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell Death Differentiation. https://doi.org/10.1038/s41418-021-00869-x

Bebber, C.M., Thomas, E.S., Stroh, J., Chen, Z., Androulidaki, A., Schmitt, A., Höhne, M.N., Stüker, L., de Pádua Alves,C., Khonsari, A., Dammert, M.A., Parmaksiz, F., Tumbrink, H.L., Beleggia, F., Sos, M.L., Riemer, J., George, J., Brodesser, S., Thomas, R.K., Reinhardt, H.C. & von Karstedt, S. (2021) Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nature Communications volume 12, Article number: 2048. https://doi.org/10.1038/s41467-021-22336-4

Clemente, L.P., Rabenau, M., Tang, S., Stanka, J., Cors, E., Stroh, J., Culmsee, C., von Karstedt, S. (2020) Dynasore Blocks Ferroptosis through Combined Modulation of Iron Uptake and Inhibition of Mitochondrial Respiration. Cells Oct 9;9(10):E2259. doi: 10.3390/cells9102259

Bebber, C.M., Müller, F., Clemente, L.P., Weber, J., von Karstedt, S., (2020). Ferroptosis in Cancer Cell Biology. Cancers (Basel) 2020 Jan; 12(1):164.

Lim, J.K.M., Delaidelli, A., Minaker, S.W., Zhang, H.-F., Colovic, M., Yang, H., Negri, G.L., Karstedt, von, S., Lockwood, W.W., Schaffer, P., et al. (2019). Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc. Natl. Acad. Sci. U.S.A. 1092, 201821323.

Hartwig, T.*, Montinaro, A.*, von Karstedt, S.*, Sevko, A., Surinova, S., Chakravarthy, A., Taraborrelli, L., Draber, P., Lafont, E., Arce Vargas, F., et al. (2017). The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. Mol. Cell 65, 730–742.e5. * These authors contributed equally to this work.

von Karstedt, S., Conti, A., Nobis, M., Montinaro, A., Hartwig, T., Lemke, J., Legler, K., Annewanter, F., Campbell, A.D., Taraborrelli, L., et al. (2015). Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell 27, 561–573.

von Karstedt, S.*, Montinaro, A.*, and Walczak, H. (2017). Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat. Rev. Cancer 17, 352–366. * These authors contributed equally to this work.

Patents: Named inventors: H. Walczak, S. von Karstedt; Methods for treating cancer (publication date 08.01.2015; WO2015001345)